Clinical Trials Brief | April 20, 2026
This week's five signals cover FDA's transparency crackdown on unreported trial results, new draft guidance on genome editing safety assessment using next-generation sequencing, a PRAC safety action on the epilepsy drug Ontozry, post-marketing safety requirements for Lilly's obesity pill Foundayo, and two independent pancreatic cancer trials reporting doubled survival in the same week.
FDA tells 2,200 drug developers to post their trial results or face consequences
What changed
On March 30, 2026, FDA sent messages to more than 2,200 companies and researchers associated with more than 3,000 registered clinical trials that do not appear to have submitted required results to ClinicalTrials.gov. The agency's internal analysis found 29.6% of studies highly likely to fall under mandatory reporting requirements have no results posted. FDA announced the initiative publicly on April 13, 2026, and said it is seeking voluntary compliance before considering enforcement actions including civil monetary penalties of up to $15,107 per day.
Why it matters
Trial transparency requirements have existed since 2007 under FDAAA, but enforcement has historically been weak. This is the most concrete enforcement-adjacent signal in recent memory: 2,200+ sponsors, 3,000+ trials, a specific noncompliance rate, and an explicit warning about escalation to formal noncompliance notices and financial penalties. The stated concern is not only about missing data, but about publication bias that overrepresents successes and obscures failures.
Takeaway
The gap between trial registration requirements and actual public reporting has been an open problem for years. These letters suggest regulators may be done waiting for voluntary improvement.
Sources
This item is grounded in FDA's April 13, 2026 press announcement and Greenberg Traurig's April 21, 2026 legal analysis of the enforcement implications.
FDA wants a clearer safety standard for genome editing before it reaches more patients
What changed
On April 14, 2026, FDA published draft guidance titled 'Safety Assessment of Genome Editing in Human Gene Therapy Products Using Next-Generation Sequencing.' The document provides recommendations on sequencing strategies, sample selection, analysis parameters, and reporting to evaluate potential safety risks including off-target editing and chromosomal translocations. It applies to both ex vivo and in vivo gene therapy products and is intended to support IND applications and Biologics License Applications. Public comments are due within 90 days.
Why it matters
Gene therapy development is accelerating, but the nonclinical safety toolkit has not always kept pace with the complexity of genome editing. This guidance gives sponsors a more concrete framework for demonstrating that their editing approach is safe enough to justify human exposure, rather than leaving the assessment approach open to interpretation. It builds on FDA's January 2024 guidance on genome editing and the February 2026 framework for individualized ultra-rare disease therapies.
Takeaway
The practical signal is not that genome editing is becoming harder to develop. It is that FDA is standardizing how sponsors should prove safety at the nonclinical stage, which should reduce ambiguity and speed up well-prepared IND submissions.
Sources
This item is grounded in the FDA press announcement published April 14, 2026 and the Federal Register notice published April 15, 2026.
PRAC adds liver-injury monitoring requirements for the epilepsy drug Ontozry
What changed
In PRAC meeting highlights from April 7-10, 2026, EMA said the committee identified cases of severe liver injury and hepatic failure with the epilepsy medicine Ontozry (cenobamate), particularly when used with other anti-seizure medications. PRAC recommended adding liver injury as a rare side effect to the product information and requiring liver function tests before treatment initiation and throughout treatment.
Why it matters
This is not a dramatic product withdrawal, but it is a clear example of how post-market safety monitoring translates into concrete prescriber-level obligations. The requirement for liver function testing before and during treatment changes clinical workflow, not just labeling language.
Takeaway
The useful reading here is not alarm about cenobamate specifically, but how regulators turn safety signals into actionable monitoring requirements that affect real clinical practice.
Sources
This item is grounded in EMA's published PRAC meeting highlights for April 7-10, 2026.
FDA requires post-marketing safety studies for Lilly's newly approved obesity pill
What changed
On April 14, 2026, Reuters and CNBC reported that the FDA required Eli Lilly to conduct post-marketing studies for its newly approved oral obesity drug Foundayo. The required studies cover liver injury, cardiovascular events, delayed gastric emptying, and lactation effects.
Why it matters
The GLP-1 and obesity drug category is the most commercially watched therapeutic area in pharma right now. This requirement shows that FDA approval is not the finish line for safety evaluation, especially in a drug class with massive expected patient exposure. The scope of the required studies, covering liver, cardiac, gastric, and lactation risks, suggests regulators want a much fuller picture than what the pre-approval program provided.
Takeaway
For the most high-profile drug approvals, the real safety conversation starts after approval. Post-marketing requirements in a category this large are a signal that both regulators and the market are watching closely.
Sources
This item is grounded in Reuters and CNBC reporting from April 14, 2026.
Two independent trials report doubled survival in metastatic pancreatic cancer in the same week
What changed
On April 13-14, 2026, two independent pancreatic cancer trials reported results in the same week. A Phase 2 trial published in Nature Medicine found that elraglusib plus chemotherapy doubled one-year survival (44% vs 22%) with a 38% reduction in death risk across 233 patients at 60 sites in six countries. Separately, Revolution Medicines announced that the Phase 3 RASolute 302 trial of daraxonrasib showed median overall survival of 13.2 months versus 6.7 months for chemotherapy alone (HR 0.40), meeting all primary and secondary endpoints.
Why it matters
Metastatic pancreatic cancer has been one of the most treatment-resistant cancers for decades. Two independent programs reporting this level of survival improvement in the same week is rare and clinically significant. The two drugs use completely different mechanisms: elraglusib targets the Wnt pathway while daraxonrasib is a multi-selective RAS inhibitor, suggesting the field may be opening up from multiple directions.
Takeaway
One positive pancreatic cancer trial would be news. Two in the same week, from different mechanisms and independent programs, is the kind of convergent signal that suggests the treatment landscape for this disease may be genuinely shifting.
Sources
This item is grounded in Northwestern University's April 14, 2026 press release, GlobeNewsWire's April 13, 2026 announcement from Revolution Medicines, and Medical Xpress coverage.